XtalPi’s RTX-117 Wins NMPA IND for CMT Therapy
ReviR Therapeutics, an incubated company of XtalPi (HKG: 2228), announced that RTX-117 has received Investigational...
ReviR Therapeutics
ReviR Therapeutics Secures FDA Orphan Drug Designation for RTX‑117, Targeting Charcot‑Marie‑Tooth Disease
ReviR Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan...
Asieris Partners with ReviR Therapeutics for Urogenital Cancer Research
China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) has struck a...